|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Pliant Therapeutics, Inc. (PLRX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
62,906,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Co.'s focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-ss. Co.'s main product candidate, PLN-74809, is a dual selective inhibitor of avss6 and avss1 integrins that Co. is developing for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. Co.'s second product candidate, PLN-1474, is a selective inhibitor of avss1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which Co. has partnered with Novartis Institutes for Biomedical Research, Inc.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
60,780 |
243,411 |
2,717,120 |
| Total Sell Value |
$0 |
$1,047,240 |
$4,403,797 |
$18,310,240 |
| Total People Sold |
0 |
5 |
5 |
6 |
| Total Sell Transactions |
0 |
5 |
14 |
45 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cummings Keith Lamont |
Chief Financial Officer |
• – – |
2021-03-05 |
4 |
OE |
$2.08 |
$41,600 |
D/D |
20,000 |
47,621 |
|
- |
|
| Coulie Bernard |
President and CEO |
• • – |
2021-02-16 |
4 |
AS |
$32.10 |
$114,352 |
I/I |
(3,500) |
463,817 |
|
- |
|
| Coulie Bernard |
President and CEO |
• • – |
2021-01-14 |
4 |
AS |
$26.20 |
$92,325 |
I/I |
(3,500) |
467,317 |
|
- |
|
| Cummings Keith Lamont |
Chief Financial Officer |
• – – |
2020-12-21 |
4 |
OE |
$2.08 |
$9,360 |
D/D |
4,500 |
27,621 |
|
- |
|
| Lefebvre Eric |
Chief Medical Officer |
• – – |
2020-12-18 |
4 |
AS |
$26.17 |
$331,752 |
D/D |
(12,500) |
162,080 |
|
- |
|
| Coulie Bernard |
President and CEO |
• • – |
2020-12-14 |
4 |
AS |
$27.32 |
$95,790 |
I/I |
(3,500) |
470,817 |
|
- |
|
| Cummings Keith Lamont |
Chief Financial Officer |
• – – |
2020-12-01 |
4 |
AS |
$28.24 |
$562,035 |
D/D |
(18,734) |
23,121 |
|
- |
|
| Cummings Keith Lamont |
Chief Financial Officer |
• – – |
2020-12-01 |
4 |
OE |
$2.08 |
$68,539 |
D/D |
18,734 |
41,855 |
|
- |
|
| Green Jeremy |
10% Owner |
– – • |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
I/I |
1,910,657 |
1,910,657 |
|
- |
|
| Hull Hans |
Chief Business Officer |
• – – |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
I/I |
3,821 |
3,821 |
|
- |
|
| Hull Hans |
Chief Business Officer |
• – – |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,079 |
117,246 |
|
- |
|
| Howes Barbara |
Chief Human Resource Officer |
• – – |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,821 |
24,799 |
|
- |
|
| Coulie Bernard |
President and CEO |
• • – |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
I/I |
25,397 |
474,317 |
|
- |
|
| Huh Hoyoung |
Director |
– • – |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
I/I |
139,860 |
239,619 |
|
- |
|
| Trv Gp Iv, Llc |
10% Owner |
– – • |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
I/I |
2,132,867 |
2,132,867 |
|
- |
|
| Trv Gp Iv, Llc |
10% Owner |
– – • |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,559,440 |
5,839,160 |
|
- |
|
| Exter Neil |
Director |
– • – |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
I/I |
0 |
0 |
|
- |
|
| Cummings Keith Lamont |
Chief Financial Officer |
• – – |
2020-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
3,821 |
23,121 |
|
- |
|
| Curnutte John T |
Director |
– • – |
2020-06-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
29,278 |
|
- |
|
| Lefebvre Eric |
Chief Medical OfficerOfficer |
• – – |
2020-06-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
174,580 |
|
- |
|
| Bruhn Suzanne Louise |
Director |
– • – |
2020-06-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,081 |
|
- |
|
| Hull Hans |
Chief Business OfficerOfficer |
• – – |
2020-06-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
27,970 |
|
- |
|
| Hull Hans |
Chief Business OfficerOfficer |
• – – |
2020-06-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
112,167 |
|
- |
|
| Trv Gp Iv, Llc |
10% Owner |
– – • |
2020-06-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
279,720 |
|
- |
|
| Cummings Keith Lamont |
Chief Financial OfficerOfficer |
• – – |
2020-06-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,300 |
|
- |
|
132 Records found
|
|
Page 5 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
